top of page

7 MM


Number of people in the U.S. living with Alzheimer’s Disease

$321 BN


Costs to U.S. economy (on top of $271 Billion in unpaid caregiving)



FDA Approved drugs to modify Alzheimer's Disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. It is the most common cause of dementia in older adults, accounting for approximately 60-80% of dementia cases worldwide.


According to the Alzheimer’s Association, an estimated 6.9 million Americans age 65 and older are living with Alzheimer's in 2024. Seventy-three percent are age 75 or older. About 1 in 9 people age 65 and older (10.9%) has Alzheimer's. Almost two-thirds of Americans with Alzheimer's are women.


Alzheimer's disease is a major public health concern worldwide, with a substantial and growing prevalence. Due to population aging and other demographic trends, the prevalence of Alzheimer's disease is expected to rise significantly in the coming decades, posing substantial challenges for healthcare systems, caregivers, and society as a whole.

A devastating disease for patients, their caregivers and society


Alzheimer's disease imposes a significant burden on affected individuals, caregivers, families, and society as a whole, including healthcare costs, caregiver burden, and loss of productivity.

Efforts to raise awareness, improve early detection and diagnosis, and develop effective prevention and treatment strategies are essential for addressing the growing public health challenge posed by Alzheimer's disease.

The diagnosis of Alzheimer's disease involves a comprehensive assessment of cognitive function, medical history, physical examination, and laboratory tests to rule out other possible causes of dementia. Imaging studies, such as MRI or PET scans, may be used to evaluate brain structure and function.


While the exact cause of Alzheimer's disease is not fully understood, it is believed to involve a complex interplay of genetic, environmental, and lifestyle factors, leading to the accumulation of abnormal protein aggregates in the brain, including beta-amyloid plaques and tau tangles, synaptic dysfunction, and neuronal loss. While most cases of Alzheimer's disease are sporadic, certain genetic factors, such as mutations in the genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2), are associated with rare familial forms of the disease.

Currently, there are no drugs approved to modify the disease. Drugs that have been approved to date are prescribed to improve symptomatology such as cognitive function, memory loss and confusion, and optimize symptomatic relief. There is a need for disease-modifying treatments that can slow or halt the progression of Alzheimer's disease by targeting the underlying mechanisms of neurodegeneration.

Overall, Alzheimer's disease involves a multidisciplinary approach that integrates pharmacological interventions, behavioral strategies, and supportive care to optimize symptom management, improve quality of life, and enhance overall well-being for individuals affected by the disease. Our goal is to bring NT-201 into the clinic and to showcase that it can modify the course of the disease for patients and help to address the growing public health burden that it causes.



Alzheimers Assocation
Alzheimers Foundation of America
CDC Logo
bottom of page